C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016

Publication ID: GMD0516140  
Publication Date: May 31, 2016  
Pages: 38  
Publisher: Global Markets Direct  
Countries: Global [1]

$3,500.00

Publication License Type *

- SINGLE USER LICENSE (PDF), $3,500.00
- SITE LICENSE (PDF), $7,000.00
Diseases [2]
Pharma & Healthcare [3]
Description:

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016’, provides in depth analysis on C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted pipeline therapeutics.

The report provides comprehensive information on the C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20
therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1)
- The report reviews C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

**Table Of Contents:**

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) Overview 6
Therapeutics Development 7
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Stage of Development 7
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Therapy Area 8
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Indication 9
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-
Alpha Receptor or CD191 or CCR1) - Products under Development by Companies 12
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-
Alpha Receptor or CD191 or CCR1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-
Alpha Receptor or CD191 or CCR1) - Companies Involved in Therapeutics Development 18
Bristol-Myers Squibb Company 18
ChemoCentryx, Inc. 19
Ligand Pharmaceuticals, Inc. 20
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-
Alpha Receptor or CD191 or CCR1) - Drug Profiles 21
BMS-457 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
CCX-354 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
CCX-9588 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Drug to Antagonize CCR1 for Oncology - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
PS-031291 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecule to Antagonize CCR1 for Undisclosed Indication - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 28
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Dormant Projects 29

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Discontinued Products 30

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Featured News & Press Releases 31

Apr 18, 2016: ChemoCentryx Announces Immuno-Oncology Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting 31

Jun 08, 2012: ChemoCentryx Announces Peer-Reviewed Publication Of Positive Phase II Clinical Data With CCX354 In Patients With Rheumatoid Arthritis 31

Nov 08, 2011: ChemoCentryx Reports Clinical Efficacy For CCX354 In Phase II Study In Patients With Rheumatoid Arthritis 32

Nov 09, 2010: ChemoCentryx Reports Favorable Phase I Results For CCX354 In Rheumatoid Arthritis At Annual American College Of Rheumatology Meeting 33

Jun 17, 2010: ChemoCentryx Reports Positive Phase I Study Results For CCX354 34

Dec 16, 2009: ChemoCentryx Initiates Phase 2 Clinical Trial Of CCX354 For The Treatment Of Rheumatoid Arthritis 35

May 13, 2008: ChemoCentryx Initiates Clinical Trial Of CCX354 For The Treatment Of Inflammatory Disease 35

Feb 11, 2008: Pharmacopeia Nominates PS031291 For Development 36

Appendix 37

Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 17
Pipeline by Bristol-Myers Squibb Company, H1 2016 18
Pipeline by ChemoCentryx, Inc., H1 2016 19
Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 20
Dormant Projects, H1 2016 29
Discontinued Products, H1 2016 30

List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Actions, H1 2016 15
Number of Products by Stage and Routes of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 17

Companies Mentioned:

Bristol-Myers Squibb Company
ChemoCentryx, Inc.
Ligand Pharmaceuticals, Inc.

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.
Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL: https://www.marketresearchreports.com/global-markets-direct/c-c-chemokine-receptor-type-1-hm145-or-lc78-receptor-or-macrophage

Links